Formulation and Drug Delivery

PHE Analysis Demonstrates Efficacy of COVID Vaccines Against Delta Variant

June 18, 2021

Recent analysis has shown that two doses of COVID-19 vaccines are highly effective against hospitalization as a result of infection with the Delta variant of COVID-19.

Sanofi Facility for Flu Vaccine Licensed by FDA

June 17, 2021

Sanofi’s new Pennsylvania facility expands production of Fluzone High-Dose Quadrivalent flu vaccine.

Evonik and Stanford University Partner to Develop mRNA Drug Delivery Technology

June 16, 2021

Evonik and Stanford University have signed a research collaboration to develop and market a new drug delivery platform for mRNA and gene therapy.

Novavax Reports on Two Vaccine Efficacy Studies

June 15, 2021

Novavax’s COVID-19 vaccine is 90.4% effective and maintains efficacy when administered with an influenza vaccine.

FDA Authorizes Use of Drug Substance for Janssen COVID-19 Vaccine

June 14, 2021

The agency approved two batches of drug substance manufactured at the Emergent BioSolutions facility in Baltimore for use in the Janssen COVID-19 vaccine.

Novel Automated Process May Speed Up Development of New Medicines

June 11, 2021

Researchers from the Chalmers University of Technology and AstraZeneca have developed a new method of detecting and testing lipid nanoparticles.

Lab-Scale Capsule Filler Provides Flexibility for Dosing Small Quantities

June 10, 2021

New features of Syntegon’s GKF 60 capsule filler include a piezo dosing system, an Automated Process Development tool, and quick changeover to containment.

Pfizer and BioNTech COVID-19 Vaccine Authorized in UK and Europe for Adolescents

June 08, 2021

The vaccine is now authorized for ages 12 and older in European Union member states and the UK.

AGC Biologics to Supply More Plasmid DNA for Pfizer-BioNTech COVID-19 Vaccine

June 08, 2021

AGC Biologics has partnered with BioNTech to further supply plasmid DNA starting material from its Heidelberg, Germany, facility for the Pfizer-BioNTech COVID-19 vaccine.

FDA Grants Accelerated Approval for Biogen’s Alzheimer’s Drug

June 07, 2021

FDA has granted accelerated approval to Biogen for Aduhelm (aducanumab), a new mAb treatment for Alzheimer’ disease.